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 Abstract 
Cancer treatment with polymer-bound cytostatic drugs and its potentiation 
through immunomodulation 
 
Poly[N-2-(hydroxypropyl)-methacrylamide] (PHPMA) is a synthetic water 
soluble and biocompatible polymer which can be used as a carrier of a cytostatic drug 
and an antibody as a targeting moiety. The antibody ensures the site-specific delivery of 
the conjugate. Nevertheless, even polymeric conjugates without any tumor-specific 
targeting moiety are passively accumulated within solid tumors via so called Enhanced 
Permeability and Retention (EPR) effect, in case that their molecular wight is at least 40 
kDa. Antibody-targeted polymeric drugs have been shown previously to have a 
cytostatic activity in vitro and an antitumor activity in vivo. Since treatment of cancer 
diseases in practice is far from such ideal conditions and many tumors have no strictly 
specific marker suitable for targeted therapy, upgrading of the treatment efficacy 
represents the major challenge. One of the possible ways how to improve insufficient 
chemotherapy outcome can be using of a combination of polymer-bound cytostatic drug 
and potent immunomodulation able to induce a robust anti-cancer immune response. 
In this study, we have used B cell leukemia BCL1 as an experimental tumor 
model. BCL1 cells express surface IgM with an unique idiotype which is thus a perfect 
tumor-specific target. BCL1-specific IgM idiotype can be recognized by monoclonal 
antibody (mAb) produced by B1 hybridoma. We used suboptimal treatment protocols 
combining B1 mAb-targeted polymeric drug with depletion of T regulatory cells or 
application of poly I:C. Immunocomplexes formed by murine IL-2 and anti-mouse IL-2 
mAb S4B6 were previously reported to strongly stimulate expansion of CD122hi cell 
populations, namely CD8+ memory T cells and NK cells, which are essential 
in anti-tumor immunity. Immunotherapy with IL-2 immunocomplexes can be further 
improved by co-injection of IL-12 which strongly increases an expression of molecules 
involved in T cell and NK cell effector functions. We tested whether this approach can 
potentiate the effect of a conjugate containing irrelevant human polyclonal antibody 
instead of specific B1 mAb. 
While the suboptimal protocols using low doses of B1 mAb-targeted polymeric 
conjugate or using conjugate containing irrelevant antibody lead to only poor 
therapeutic efficacy, we were able to reach significantly better outcome when the 
immunomodulation was applied. Thus we suggest that immunomodulation represents a 
suitable improvement of polymeric drug-based therapy and consider the IL-2 
immunocomplexes as a promising component of the advanced treatment schedules. 
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